Differences between CML in children and adults & the potential of asciminib in pediatric patient

3 Views

07/08/23

Nobuko Hijiya, MD, Columbia University Irving Medical Center, New York City, NY, comments on the key differences in the biology of chronic myeloid leukemia (CML) in children and adults, and highlights the need for new treatment strategies in children, such as asciminib, which has a better tolerability profile than other tyrosine kinase inhibitors (TKIs) and may increase the likelihood of patients achieving treatment-free remission (TFR). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.